Galapagos awarded Innovative Enterprise qualification in France>
Galapagos awarded Innovative Enterprise qualification in France
(Thomson Reuters ONE) - Mechelen, Belgium; 30 June 2009 - Galapagos NV (Euronext: GLPG)announces that it has been granted the Innovative Enterprisequalification (Entreprises Innovantes au titre des FCPI) from theFrench governmental organization OSEO that supports innovation andgrowth of SMEs. French private investors are eligible to receivesignificant tax advantages for participating in funds which invest inFCPI qualified companies such as Galapagos.Innovation-focused mutual funds (FCPI) were created by the French1997 Finance Act in order to support the development of innovativesmall firms in France. The Act has since been extended and amendedto increase the tax benefits gained from holding FCPI units. FCPIfunds are subject to approval and audit by the French financialmarkets authority AMF. Since its inception in 1997, ?4.4 billion hasbeen raised by FCPI funds."Following the OSEO's rigorous review process, Galapagos has beenrecognized as the type of innovative company the French government islooking to support and stimulate," said Onno van de Stolpe,Galapagos' CEO. "We are pleased that the acquisition of our Frenchresearch center in 2006 has brought this additional benefit to theGalapagos Group. Through this qualification, Galapagos is noweligible for investments by FCPI funds, opening the opportunity to anew category of French institutional investors."About OSEOOSEO was created in 2005 by bringing together ANVAR (FrenchInnovation Agency) and BDPME (Development Bank for SMEs). OSEO'smission is to provide assistance and financial support to French SMEsin the most decisive phases of their life cycle: start up,innovation, development, business transfer/buy out. By sharing therisk, OSEO facilitates the access of SMEs to financing by bankingpartners and equity capital investors. More info at: www.oseo.fr.About GalapagosGalapagos (Euronext: GLPG; OTC: GLPYY) is a drug discovery anddevelopment company with small molecule programs in bone and jointdiseases, bone metastasis, cachexia, anti-infectives and metabolicdiseases. It has established risk sharing alliances with GSK,Janssen Pharmaceutica, Eli Lilly and Merck. Through an alliance withMorphoSys, Galapagos is also developing new antibody therapies inbone and joint diseases. Its division BioFocus DPI offers a fullsuite of target-to-drug discovery products and services topharmaceutical and biotech companies and to patient foundations,encompassing target discovery and validation, screening and drugdiscovery through to delivery of pre-clinical candidates. Galapagoscurrently employs 490 people and operates facilities in sixcountries, with global headquarters in Mechelen, Belgium. More infoat: www.glpg.com.CONTACTGalapagos NVElizabeth Goodwin, Director Investor RelationsTel: +31 62 291 6240ir(at)glpg.comThis release may contain forward-looking statements, including,without limitation, statements containing the words "believes,""anticipates," "expects," "intends," "plans," "seeks," "estimates,""may," "will," "could," "stands to," and "continues," as well assimilar expressions. Such forward-looking statements may involveknown and unknown risks, uncertainties and other factors which mightcause the actual results, financial condition, performance orachievements of Galapagos, or industry results, to be materiallydifferent from any historic or future results, financial conditions,performance or achievements expressed or implied by suchforward-looking statements. Given these uncertainties, the reader isadvised not to place any undue reliance on such forward-lookingstatements. These forward-looking statements speak only as of thedate of publication of this document. Galapagos expressly disclaimsany obligation to update any such forward-looking statements in thisdocument to reflect any change in its expectations with regardthereto or any change in events, conditions or circumstances on whichany such statement is based, unless required by law or regulation.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Bombardier Sells Two Q400 NextGen Airliners to Porter>
">
" alt="Analyst & Investor Teach-In>
">
Datum: 30.06.2009 - 01:30 Uhr
Sprache: Deutsch
News-ID 1002385
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
London
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 542 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos awarded Innovative Enterprise qualification in France>
"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
